Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Moderate Buy” by Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $39.25.

Several analysts have issued reports on the stock. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a report on Monday, January 5th. HC Wainwright lifted their price objective on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Chardan Capital increased their target price on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a report on Monday, January 5th. Wolfe Research started coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 13,430 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $32.27, for a total value of $433,386.10. Following the sale, the director directly owned 49,124 shares of the company’s stock, valued at approximately $1,585,231.48. This trade represents a 21.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 3,978 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $32.28, for a total transaction of $128,409.84. Following the transaction, the general counsel directly owned 11,831 shares of the company’s stock, valued at $381,904.68. This trade represents a 25.16% decrease in their position. The disclosure for this sale is available in the SEC filing. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. boosted its position in Stoke Therapeutics by 24.7% in the 4th quarter. Invesco Ltd. now owns 259,543 shares of the company’s stock valued at $8,238,000 after buying an additional 51,468 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Stoke Therapeutics during the fourth quarter valued at about $330,000. Tudor Investment Corp ET AL purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $613,000. Readystate Asset Management LP acquired a new position in shares of Stoke Therapeutics in the fourth quarter worth about $922,000. Finally, RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares in the last quarter.

Stoke Therapeutics Trading Up 2.4%

Shares of NASDAQ STOK opened at $35.48 on Friday. The company’s 50-day moving average price is $32.19 and its 200 day moving average price is $28.94. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $39.81. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of 52.96 and a beta of 1.07.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.